STAT+: Bristol Myers Squibb partners with China’s Hengrui Pharma on a dozen drugs
Bristol Myers Squibb and China's Hengrui Pharma are teaming up to advance more than a dozen early-stage drugs, in a deal worth up to $15.2 billion.
Original Source
Read the full article at Statnews →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.